Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
30
datasets available to search
ShareScore release 0.9.0
Dataset results
30 results for “polygenic risk score”
UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits
<p>Summary-level GWAS data for 53 traits generated by <a href="https://www.genomicsplc.com/">Genomics plc</a> as presented in:</p> <p>Thompson D. et al. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits (<a href="https://doi.org/10.1101/2022.06.16.22276246">https://doi.org/10.1101/2022.06.16.22276246</a>)</p> <p>If you have any questions or comments regarding these files, please contact Genomics plc at <a href="mailto:research@genomicsplc.com">research@genomicsplc.com</a></p> <p><strong>NOTES</strong></p> <p>These analyses were carried out using the full UK Biobank (UKB) imputation data release (v3b). After removal of exclusions and withdrawals, a subset of 337,151 UKB individuals, the White British Unrelated (WBU) subgroup, was defined as the intersection of two sample groups created by Bycroft et al 2018 (Nature 562, 203-209): the ‘White British ancestry’ group (UKB Data Field 22006) and the ‘used in genetic principal components’ group (UKB Data Field 22020), the latter being high quality samples that were filtered to avoid closely related individuals. All GWAS analyses were performed on the WBU subgroup.</p> <p>Phenotypes were defined as described in Supplementary Table 1 ‘Phenotype definitions’ using a combination of Hospital Episode Statistics, Cancer Registry reports (where applicable) and self-report responses, with the exception of coronary artery disease (CAD). GWAS data was generated for both a “narrow” and a “broad” definition of CAD. The former was used as part of the training data for the Enhanced CAD PRS, the latter was used as part of the training data for the Enhanced CVD PRS. The phenotype definitions for “narrow” and a “broad” CAD are as follows:</p> <table> <tbody> <tr> <td>Narrow CAD<br> (includes angina)</td> <td>ICD10 codes (where .X indicates all subcodes) from both hospital and death records: I21, I22, I23, I24.1, I25.2, I20.X. ICD9 codes: 410-412, 42979, 413.X. OPCS-4 codes (K40.1–40.4, K41.1–41.4, K45.1–45.5,K49.1–49.2, K49.8–49.9, K50.2, K75.1–75.4, K75.8–75.9), self-reported heart attack (UKB codes 1075 in field 20002; code 1 in field 6150), self-reported coronary angioplasty (ptca) or coronary artery bypass graft (UKB codes 1070 and 1095 in field 20004), self-reported angina.</td> </tr> <tr> <td>Broad CAD<br> (includes angina and all ischaemic heart disease)</td> <td>As for Narrow CAD, plus ICD10 codes I24.X, I25X, and ICD9 codes 414.X (where .X indicates all subcodes).</td> </tr> </tbody> </table> <p>Note that there is no GWAS for cardiovascular disease (CVD) per se. This is because the UKB training data for the Enhanced CVD PRS consisted of separate GWASs for “narrow” CAD and ischaemic stroke.</p> <p>All analyses included Age at assessment, sex (for non-sex specific traits), genotyping chip, and 10 principal components as covariates.</p> <p>GWAS summary statistics for each trait were generated by applying PLINK 2.0 to the WBU subgroup, using a logistic regression for disease traits, and a linear regression model for quantitative traits. For chromosome X variants males were treated as having 0 or 2 alternative alleles.</p> <p>The results are not adjusted for genomic control.</p> <p><strong>DATA FILE CONTENT DESCRIPTION (DISEASE TRAITS)</strong></p> <table> <tbody> <tr> <td>cpra</td> <td>Variant ID in ‘CPRA’ format. Position reflects position in b37</td> </tr> <tr> <td>chrom</td> <td>Chromosome</td> </tr> <tr> <td>pos</td> <td>Position in base pairs (b37, 1-based)</td> </tr> <tr> <td>alt</td> <td>Alternative allele (effect allele)</td> </tr> <tr> <td>beta</td> <td>Effect size (log odds ratio)</td> </tr> <tr> <td>standard_error</td> <td>Standard error of beta</td> </tr> <tr> <td>minus_log10_p</td> <td>Minus log(base 10) of P-value</td> </tr> <tr> <td>ref</td> <td>Reference allele (non-effect allele)</td> </tr> <tr> <td>ncase</td> <td>Number of cases</td> </tr> <tr> <td>ncontrol</td> <td>Number of controls</td> </tr> </tbody> </table> <p><strong>DATA FILE CONTENT DESCRIPTION (QUANTITATIVE TRAITS)</strong></p> <table> <tbody> <tr> <td>cpra</td> <td>Variant ID in ‘CPRA’ format. Position reflects position in b37</td> </tr> <tr> <td>chrom</td> <td>Chromosome</td> </tr> <tr> <td>pos</td> <td>Position in base pairs (b37, 1-based)</td> </tr> <tr> <td>alt</td> <td>Alternative allele (effect allele)</td> </tr> <tr> <td>beta</td> <td>Effect size</td> </tr> <tr> <td>standard_error</td> <td>Standard error of beta</td> </tr> <tr> <td>minus_log10_p</td> <td>Minus log(base 10) of P-value</td> </tr> <tr> <td>ref</td> <td>Reference allele (non-effect allele)</td> </tr> <tr> <td>ntotal</td> <td>Total sample size</td> </tr> </tbody> </table> <p><strong>FILE NAMES</strong></p> <p>The following is a list of traits and their corresponding file names.</p> <p><em><strong>DISEASE TRAITS</strong></em></p> <table> <tbody> <tr> <td>Age-related macular degeneration</td> <td>amd_strict_UKB_WBU.csv.gz</td> </tr> <tr> <td>Alzheimer's disease</td> <td>alzheimers_disease_UKB_WBU.csv.gz</td> </tr> <tr> <td>Asthma</td> <td>asthma_UKB_WBU.csv.gz</td> </tr> <tr> <td>Atrial fibrillation</td> <td>atrial_fibrillation_UKB_WBU.csv.gz</td> </tr> <tr> <td>Bipolar disorder</td> <td>bipolar_disorder_UKB_WBU.csv.gz</td> </tr> <tr> <td>Bowel cancer</td> <td>CRC_UKB_WBU.csv.gz</td> </tr> <tr> <td>Breast cancer</td> <td>BC_UKB_WBU_women.csv.gz</td> </tr> <tr> <td>Coeliac disease</td> <td>celiac_disease_UKB_WBU.csv.gz</td> </tr> <tr> <td>Narrow coronary artery disease</td> <td>NARROW_CAD_UKB_WBU.csv.gz</td> </tr> <tr> <td>Broad coronary artery disease</td> <td>BROAD_CAD_UKB_WBU.csv.gz</td> </tr> <tr> <td>Crohn's disease</td> <td>crohns_disease_UKB_WBU.csv.gz</td> </tr> <tr> <td>Epithelial ovarian cancer</td> <td>OC_UKB_WBU.csv.gz</td> </tr> <tr> <td>Hypertension</td> <td>HT_UKB_WBU.csv.gz</td> </tr> <tr> <td>Ischaemic stroke</td> <td>IS_stroke_UKB_WBU.csv.gz</td> </tr> <tr> <td>Melanoma</td> <td>melanoma_UKB_WBU.csv.gz</td> </tr> <tr> <td>Multiple sclerosis</td> <td>multiple_sclerosis_UKB_WBU.csv.gz</td> </tr> <tr> <td>Osteoporosis</td> <td>OP_WBU_training.csv.gz</td> </tr> <tr> <td>Prostate cancer</td> <td>PC_UKB_WBU.csv.gz</td> </tr> <tr> <td>Parkinson's disease</td> <td>parkinsons_disease_UKB_WBU.csv.gz</td> </tr> <tr> <td>Primary open angle glaucoma</td> <td>POAG_WBU_training.csv.gz</td> </tr> <tr> <td>Psoriasis</td> <td>psoriasis_UKB_WBU.csv.gz</td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>rheumatoid_arthritis_UKB_WBU.csv.gz</td> </tr> <tr> <td>Schizophrenia</td> <td>schizophrenia_UKB_WBU.csv.gz</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>lupus_UKB_WBU.csv.gz</td> </tr> <tr> <td>Type 1 diabetes</td> <td>t1d_UKB_WBU.csv.gz</td> </tr> <tr> <td>Type 2 diabetes</td> <td>T2D_UKB_WBU.csv.gz</td> </tr> <tr> <td>Ulcerative colitis</td> <td>ulcerative_colitis_UKB_WBU.csv.gz</td> </tr> <tr> <td>Venous thromboembolic disease</td> <td>VTE_UKB_WBU.csv.gz</td> </tr> </tbody> </table> <p><em><strong>QUANTITATIVE TRAITS</strong></em></p> <table> <tbody> <tr> <td>Age at menopause</td> <td>age_at_menopause_UKB_WBU.csv.gz</td> </tr> <tr> <td>Apolipoprotein A1</td> <td>apolipoprotein_a1_UKB_WBU.csv.gz</td> </tr> <tr> <td>Apolipoprotein B</td> <td>apolipoprotein_b_UKB_WBU.csv.gz</td> </tr> <tr> <td>Body mass index</td> <td>bmi_UKB_WBU.csv.gz</td> </tr> <tr> <td>Calcium</td> <td>calcium_UKB_WBU.csv.gz</td> </tr> <tr> <td>Docosahexaenoic acid</td> <td>docosahexaenoic_acid_UKB_WBU.csv.gz</td> </tr> <tr> <td>Estimated bone mineral density T-score</td> <td>BMD_WBU_training.csv.gz</td> </tr> <tr> <td>Estimated glomerular filtration rate (creatinine based)</td> <td>egfr_UKB_WBU.csv.gz</td> </tr> <tr> <td>Estimated glomerular filtration rate (cystatin based)</td> <td>egfr_cys_UKB_WBU.csv.gz</td> </tr> <tr> <td>Glycated haemoglobin</td> <td>hba1c_UKB_WBU_nodiabetes.csv.gz</td> </tr> <tr> <td>High density lipoprotein cholesterol</td> <td>hdl_cholesterol_UKB_WBU.csv.gz</td> </tr> <tr> <td>Height</td> <td>height_UKB_WBU.csv.gz</td> </tr> <tr> <td>Intraocular pressure</td> <td>iop_WBU_training.csv.gz</td> </tr> <tr> <td>Low density lipoprotein cholesterol</td> <td>ldl_UKB_WBU_nostatins.csv.gz</td> </tr> <tr> <td>Omega-6 fatty acids</td> <td>omega_6_fatty_acids_UKB_WBU.csv.gz</td> </tr> <tr> <td>Omega-3 fatty acids</td> <td>omega_3_fatty_acids_UKB_WBU.csv.gz</td> </tr> <tr> <td>Phosphatidylcholines</td> <td>phosphatidylcholines_UKB_WBU.csv.gz</td> </tr> <tr> <td>Phosphoglycerides</td> <td>phosphoglycerides_UKB_WBU.csv.gz</td> </tr> <tr> <td>Polyunsaturated fatty acids</td> <td>polyunsaturated_fatty_acids_UKB_WBU.csv.gz</td> </tr> <tr> <td>Resting heart rate</td> <td>resting_heart_rate_UKB_WBU.csv.gz</td> </tr> <tr> <td>Remnant cholesterol (Non-HDL, Non-LDL cholesterol)</td> <td>remnant_cholesterol__UKB_WBU.csv.gz</td> </tr> <tr> <td>Sphingomyelins</td> <td>sphingomyelins_UKB_WBU.csv.gz</td> </tr> <tr> <td>Total cholesterol</td> <td>total_cholesterol_UKB_WBU.csv.gz</td> </tr> <tr> <td>Total fatty acids</td> <td>total_fatty_acids_UKB_WBU.csv.gz</td> </tr> <tr> <td>Total triglycerides</td> <td>total_triglycerides_UKB_WBU.csv.gz</td> </tr> </tbody> </table>
Polygenic risk scores validated in patient-derived cells stratify for mitochondrial subtypes of Parkinson's disease
<p><strong>Background</strong> Parkinson’s disease (PD) is the fastest growing neurodegenerative disorder, with affected individuals expected to double during the next 20 years. This raises the urgent need to better understand the genetic architecture and downstream cellular alterations underlying PD pathogenesis, in order to identify more focused therapeutic targets. While only ∼10% of PD cases can be clearly attributed to monogenic causes, there is mounting evidence that additional genetic factors could play a role in idiopathic PD (iPD). In particular, common variants with low to moderate effect size in multiple genes regulating key neuroprotective activities may act as risk factors for PD. In light of the well-established involvement of mitochondrial dysfunction in PD, we hypothesized that a fraction of iPD cases may harbour a pathogenic combination of common variants in nuclear-encoded mitochondrial genes, ultimately resulting in neurodegeneration.</p> <p><strong>Methods</strong> to capture this mitochondria-related “missing heritability”, we leveraged on existing data from previous genome-wide association studies (GWAS) – i.e., the large PD GWAS from Nalls and colleagues. We then used computational approaches based on mitochondria-specific polygenic risk scores (mitoPRSs) for imputing the genotype data obtained from different iPD case-control datasets worldwide, including the Luxembourg Parkinson’s Study (412 iPD patients and 576 healthy controls) and the COURAGE-PD cohorts (7270 iPD cases and 6819 healthy controls).</p> <p><strong>Results</strong> applying this approach to gene sets controlling mitochondrial pathways potentially relevant for neurodegeneration in PD, we demonstrated that common variants in genes regulating <em>Oxidative Phosphorylation (OXPHOS</em>-PRS<em>)</em> were significantly associated with a higher PD risk both in the Luxembourg Parkinson’s Study (odds ratio, OR=1.31[1.14-1.50], <em>p</em>=5.4e-04) and in COURAGE-PD (OR=1.23[1.18-1.27], <em>p</em>=1.5e-29). Functional analyses in primary skin fibroblasts and in the corresponding induced pluripotent stem cells-derived neuronal progenitor cells from Luxembourg Parkinson’s Study iPD patients stratified according to the <em>OXPHOS</em>-PRS, revealed significant differences in mitochondrial respiration between high and low risk groups (<em>p</em> < 0.05). Finally, we also demonstrated that iPD patients with high <em>OXPHOS</em>-PRS have a significantly earlier age at disease onset compared to low-risk patients.</p> <p><strong>Conclusions</strong> our findings suggest that OXPHOS-PRS may represent a promising strategy to stratify iPD patients into pathogenic subgroups – in which the underlying neurodegeneration is due to a genetically defined mitochondrial burden – potentially eligible for future, more tailored mitochondrially targeted treatments.</p>
Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
<p>Supplementary Data for the manuscript: Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant. Nikita Pozdeyev, MD, PhD (ORCiD ID: 0000-0001-8574-1972), Manjiri Dighe, MD, Martin Barrio, MD, MS, Christopher Raeburn, MD, Harry Smith, MS, Matthew Fisher, MS, Sameer Chavan, MS, Nicholas Rafaels, MS, Jonathan A. Shortt, PhD, Meng Lin, PhD, Michael G. Leu, MD, Toshimasa Clark, MD, Carrie Marshall, MD, Bryan R. Haugen, MD, Devika Subramanian, PhD, Regeneron Genetics Center, Kristy Crooks, PhD, Christopher Gignoux, PhD, Trevor Cohen, MBChB, PhD, FACMI</p>
Genetic architecture and polygenic risk score prediction of degenerative suspensory ligament desmitis (DSLD) in the Peruvian Horse
<p class="MsoNormal"><strong>Introduction</strong>: Spontaneous rupture of tendons and ligaments is common in several species including humans. In horses, degenerative suspensory ligament desmitis (DSLD) is an important acquired idiopathic disease of a major energy-storing tendon-like structure. DSLD risk is increased in several breeds, including the Peruvian Horse. Affected horses have often been used for breeding before the disease is apparent. Breed predisposition suggests a substantial genetic contribution, but heritability and genetic architecture of DSLD have not been determined.</p> <p class="MsoNormal"><strong>Methods</strong>: To identify genomic regions associated with DSLD, we recruited a reference population of 183 Peruvian Horses, phenotyped as DSLD cases or controls, and undertook a genome-wide association study (GWAS), a regional window variance analysis using local genomic partitioning, a signatures of selection (SOS) analysis, and polygenic risk score (PRS) prediction of DSLD risk. We also estimated trait heritability from pedigrees.</p> <p class="MsoNormal"><strong>Results</strong>: Heritability was estimated in a population of 1,927 Peruvian horses at 0.22±0.08. After establishing a permutation-based threshold for genome-wide significance, 151 DSLD risk single nucleotide polymorphisms (SNPs) were identified by GWAS. Multiple regions of enriched local heritability were identified across the genome, with strong enrichment signals on chromosomes 1, 2, 6, 10, 13, 16, 18, 22, and the X chromosome. With SOS analysis, there were 66 genes with a selection signature in DSLD cases that was not present in the control group that included the <em>TGFB3</em> gene. Pathways enriched in DSLD cases included proteoglycan metabolism, extracellular matrix homeostasis, and signal transduction pathways that included the hedgehog signaling pathway. The best PRS predictive performance was obtained when we fitted 1% of top SNPs using a Bayesian Ridge Regression model which achieved the highest mean of R<sup>2</sup> on both the probit and logit liability scales, indicating a strong predictive performance.</p> <p><strong>Discussion</strong>: We conclude that within-breed GWAS of DSLD in the Peruvian Horse has further confirmed that moderate heritability and a polygenic architecture underlies the trait and identified multiple DSLD SNP associations in novel tendinopathy candidate genes influencing disease risk. Pathways enriched with DSLD risk variants include ones that influence glycosaminoglycan metabolism, extracellular matrix homeostasis, and signal transduction pathways.</p>
Cross-species analysis of genetic architecture and polygenic risk scores for non-contact ACL rupture in dogs and humans
Open the record for dataset details and reuse information.
Genetic architecture and polygenic risk score prediction of degenerative suspensory ligament desmitis (DSLD) in the Peruvian Horse
Open the record for dataset details and reuse information.
Incorporating family history of disease improves polygenic risk scores in diverse populations
<p>Code relevant to Hujoel et al. "Incorporating family history of disease improves polygenic risk scores in diverse populations"</p>
Supplemental data for: Development and validation of a polygenic risk score for stroke in the Chinese population
<div class="WordSection1"> <div class="WordSection1"> <strong>Objective</strong>: To construct a polygenic risk score (PRS) for stroke and evaluate its utility in risk stratification and primary prevention for stroke.</div> <div class="WordSection1"> </div> <div class="WordSection1"> <strong>Methods</strong>: Using meta-analytic approach and large genome-wide association results for stroke and stroke-related traits in East Asians, we generated a combined PRS (metaPRS) by incorporating 534 genetic variants in a training set of 2,872 patients with stroke and 2,494 controls. We then validated its association with incident stroke using Cox regression models in large Chinese population-based prospective cohorts comprising 41,006 individuals.</div> <div class="WordSection1"> </div> <div class="WordSection1"> <strong>Results</strong>: During a total of 367,750 person-years (mean follow-up 9.0 years), 1,227 participants developed stroke before age of 80 years. Individuals with high polygenic risk had an about 2-fold higher risk of incident stroke compared with those with low polygenic risk (HR: 1.99, 95% CI: 1.66-2.38), with the lifetime risk of stroke being 25.2% (95% CI: 22.5%-27.7%) and 13.6% (95% CI: 11.6%-15.5%), respectively. Individuals with both high polygenic risk and family history displayed the lifetime risk as high as 41.1% (95% CI: 31.4%-49.5%). Moreover, individuals with high polygenic risk achieved greater benefits in terms of absolute risk reductions from adherence to ideal fasting blood glucose and total cholesterol than those with low polygenic risk. Maintaining favorable cardiovascular health (CVH) profile could substantially mitigate the increased risk conferred by high polygenic risk to the level of the low polygenic risk (from 34.6 % to 13.2%).</div> <div class="WordSection1"> </div> <div class="WordSection1"> <strong>Conclusions</strong>: Our metaPRS has great potential for risk stratification of stroke and identification of individuals who may benefit more from maintaining ideal CVH. </div> <div class="WordSection1"> </div> <div class="WordSection1"> <strong>Classification of Evidence</strong>: This study provides Class I evidence that a meta-polygenic risk score is predictive of stroke risk.</div> <p> </p> </div>
Data from: Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes
<div> <div> <div> <p><strong>Background</strong>: Polygenic risk scores (PRS) aggregate the contribution of many risk variants to provide a personalized genetic susceptibility profile. Since sample sizes of glioma genome-wide association studies (GWAS) remain modest, there is a need to efficiently capture genetic risk using available data.</p> <p><strong>Methods</strong>: We applied a method based on continuous shrinkage priors (PRS-CS) to model the joint effects of over 1 million common variants on disease risk and compared this to an approach (PRS-CT) that only selects a limited set of independent variants that reach genome-wide significance (P<5×10-8). PRS models were trained using GWAS stratified by histological (10,346 cases, 14,687 controls) and molecular subtype (2,632 cases, 2,445 controls), and validated in two independent cohorts.</p> <p><strong>Results</strong>: PRS-CS was generally more predictive than PRS-CT with a median increase in explained variance (R2) of 24% (interquartile range=11-30%) across glioma subtypes. Improvements were pronounced for glioblastoma (GBM), with PRS-CS yielding larger odds ratios (OR) per standard deviation (OR=1.93, P=2.0×10-54 vs. OR=1.83, P=9.4×10-50) and higher explained variance (R2=2.82% vs. R2=2.56%). Individuals in the 80th percentile of the PRS- CS distribution had significantly higher risk of GBM (0.107%) at age 60 compared to those with average PRS (0.046%, P=2.4×10-12). Lifetime absolute risk reached 1.18% for glioma and 0.76% for IDH wildtype tumors for individuals in the 95th PRS percentile. PRS-CS augmented the classification of IDH mutation status in cases when added to demographic factors (AUC=0.839 vs. AUC=0.895, P=6.8×10-9).</p> <p><strong>Conclusions</strong>: Genome-wide PRS has potential to enhance the detection of high-risk individuals and help distinguish between prognostic glioma subtypes.</p> <p><strong>Citation</strong>: Nakase T, Guerra GA, Ostrom QT, et al. Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes. <em>Neuro-Oncology</em>. Published online June 25, 2024:noae112. doi:10.1093/neuonc/noae112</p> </div> </div> </div>
Genome-wide association study of polygenic risk score-defined phenotype suffers from inflated test-statistics
<p>Simulation results from running the following script 100 times: https://github.com/euffelmann/paper-ad_prs_extremes/blob/main/scripts/ad_prs_extremes_simulation.R.</p> <p>These files can be used to reproduce tables and figures in: https://github.com/euffelmann/paper-ad_prs_extremes</p>
Polygenic risk score in Africa populations: progress and challenges
<p>Polygenic Risk Score (PRS) analysis is a method that predicts the genetic risk of an individual towards targeted traits. Even when there are no significant markers, it gives evidence of a genetic effect beyond the results of Genome-Wide Association Studies (GWAS). Moreover, it selects SNPs that contribute to the disease with low effect size making it more precise at individual level risk prediction. PRS analysis addresses the shortfall of GWAS by taking into account the SNPs/alleles with low effect size but play an indispensable role to the observed phenotypic/trait variance. PRS analysis has application which investigate the genetic basis of several traits which includes rare diseases. However, the accuracy of PRS analysis depends on the genomic data of the underlying population. For instance, several studies show that obtaining higher prediction power of PRS analysis is challenging for non-Europeans. In this manuscript, we reviewed the conventional PRS methods and their application to Sub-Saharan African communities. We concluded that lack of sufficient GWAS data and tools is the limiting factor of applying PRS analysis to Sub-Saharan populations. We recommend developing Africa-specific PRS methods and tools for estimating, and analyzing Africa population data for clinical evaluation of PRSs of interest and predicting rare diseases.</p>
Polygenic Risk Score to Predict Weight Loss Intervention in Children With Obesity
ClinicalTrials.gov study NCT05466097. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.
EValuation Of poLygenic Scores and CT imAging In Risk Factor Modification in Patients With diabEtes
ClinicalTrials.gov study NCT07091162. IPD Sharing: NO. Countries: 1. Publications: 0.
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
ClinicalTrials.gov study NCT06962488. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Polygenic Risk Score for Optimizing Primary Prevention in Intermediate-Risk Populations
ClinicalTrials.gov study NCT07039123. IPD Sharing: NO. Countries: 1. Publications: 47.
Polygenic risk score in Africa populations: progress and challenges
Open the record for dataset details and reuse information.
Supplemental data for: Development and validation of a polygenic risk score for stroke in the Chinese population
Open the record for dataset details and reuse information.
Left atrial polygenic scores for "Deep Learning of Left Atrial Structure and Function Provides Link to Atrial Fibrillation Risk"
Open the record for dataset details and reuse information.
Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study
ClinicalTrials.gov study NCT06922708. IPD Sharing: YES. Countries: 0. Publications: 14.
Data from: An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.